Status:
COMPLETED
Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
Lead Sponsor:
Mateon Therapeutics
Conditions:
Cancer
Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a study evaluating the safety and effectiveness of Combretastatin A4 Phosphate (CA4P) combined with the chemotherapy drugs, carboplatin and paclitaxel. The full treatment and observation time ...
Detailed Description
This is a phase II study evaluating the safety and efficacy of Combretastatin A4 Phosphate (CA4P) combined with carboplatin and paclitaxel. Treatment is for a maximum of 6 consecutive 21-day cycles. P...
Eligibility Criteria
Inclusion
- Advanced malignancy where treatment with carboplatin and paclitaxel is warranted.
- Minimum 28-day interval from any surgical, chemotherapy or immunotherapy treatment and a 14-day interval from radiotherapy treatment.
- Radiologically measurable disease to meet MRI perfusion criteria.
- ECOG performance status less than or equal to 1.
- Life expectancy greater than 12 weeks.
- Normal ejection fraction.
Exclusion
- Uncontrolled brain metastasis.
- Significant cardiac abnormalities.
- Prior radiotherapy at the tumor site.
- Symptomatic peripheral vascular or cerebrovascular disease.
- Uncontrolled hypertension.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00113438
Start Date
March 1 2005
End Date
February 1 2007
Last Update
November 1 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112